Posts tagged drug
HCW starts Concert at buy

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.

Read More
Microbix appoints Cameron Groome as President, CEO

Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.

Read More
Titan Pharma, Walter Reed collaborating in antimalarial implants

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a cooperative research and development agreement with Walter Reed Army Institute of Research and Southwest Research Institute to evaluate development of ProNeura-based implants for a long-term regimen in the prevention of malaria.

Read More
Leerink resumes coverage of Kura at outperform

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday.

“We view Kura's lead pipeline program, tipifarnib (a farnesyltransferase inhibitor) as a safe and active drug,” writes analyst Jonathan Chang.

Read More
ProMIS in new program to identify ALS targets

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

“ProMIS will apply its proprietary computational algorithms, supplemented by other methods pioneered by ProMIS scientists, to identify specific therapeutic targets on misfolded TDP43,” SCO, Dr. Neil Cashman, said in a statement.

Read More
Soricimed announces members of CAB

Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB).

The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will provide Soricimed with ongoing expert strategic guidance on the continued clinical development of its lead anti-cancer drug candidate, SOR-C13, and its preclinical oncology pipeline.

Read More
Roth ups Titan Pharma price target to $10

Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock closed at $7.07 on Friday.

“The hook here is forced compliance,” writes analyst Scott Henry. “The implant removes the risk of noncompliant patients relapsing back to opioids, including heroin. Adding difficulty to the compliance of oral buprenorphine, Suboxone, is the high street value of the drug, which effectively can be sold to support an opioid habit,” he added.

Read More
Leerink starts Theravance Biopharma at outperform

Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday.

Theravance was formed in 2014 via a spin out from Innovia, with a diverse set of assets and a robust R&D engine.

Read More
Maxim starts ContraVir Pharma at buy

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed at 97 cents on Thursday.

“ContraVir has two programs: one in shingles (Phase 3) and one in hepatitis B (Phase 1/2), both of which can be value drivers for the company,” writes analyst Jason Kolbert.

Read More
HCW starts Windtree Therapeutics at buy

H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday.

“We believe that the company’s investigational drug/device combination, Aerosurf, which aims to deliver aerosolized surfactant to neonates with respiratory distress syndrome (RDS), is competitively positioned to be the first deliverable, noninvasive surfactant therapy in an otherwise under saturated market,” writes analyst Andrew Fein.

Read More